Answers are grounded in this paper and cite their sources.
L-162,313 is identified as the first nonpeptidic low-molecular weight compound with an agonistic effect mediated through the AT2 receptor in vivo.
In this investigation, it is demonstrated that the first nonpeptide AT(1) receptor agonist L-162,313 (1), disclosed in 1994, also acts as an agonist at the AT(2) receptor. In anesthetized rats, administration of compound 1 intravenously or locally in the duodenum increased duodenal mucosal alkaline secretion, effects that were sensitive to the selective AT(2) receptor antagonist PD-123,319. The data strongly suggest that 1 is an AT(2) receptor agonist in vivo. To the best of our knowledge, this substance is the first nonpeptidic low-molecular weight compound with an agonistic effect mediated through the AT(2) receptor.
No takes yet. Share an insight, caveat, or question.
Wan et al. (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: